{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:14:48Z","timestamp":1784052888096,"version":"3.55.0"},"reference-count":76,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Many regulatory bodies now recommend that tobacco product manufacturers provide information regarding new tobacco products\u2019 abuse liability to inform regulatory authorization of currently marketed tobacco products or new product applications (including premarket tobacco product applications in the United States). In addition, the US Food and Drug Administration (FDA) recommends including this information as part of modified risk tobacco product applications. Regulators, including FDA, and many public health officials and researchers consider abuse liability assessment a model which predicts the likelihood that the use of the tobacco product would result in addiction and be used repeatedly or even sporadically resulting in undesirable effects. Abuse liability of a new, potentially reduced harm product can also inform its ability to substitute completely for more harmful tobacco products. While many methods exist, no standard tobacco product abuse liability assessment has been established. The purpose of this review is to provide background information and practical recommendations for human abuse liability testing methods to meet tobacco regulatory needs. A combination of nicotine test product pharmacokinetic, subjective effect and\/or behavioral response, and physiological response data relative to comparator products with known abuse liability satisfies some regulatory requirements.<\/jats:p>\n               <jats:p>Implications: This review provides a practical inspection of the current, international regulatory recommendations for abuse liability assessment of tobacco and regulatory review of such information within the United States and also recommends study designs and methods for abuse liability testing of tobacco products based on scientific and regulatory knowledge. Given that tobacco product abuse liability testing is of increasing interest to regulatory bodies globally, especially with the emergence of novel tobacco products, this timely work provides background and functional recommendations for tobacco product abuse liability testing.<\/jats:p>","DOI":"10.1093\/ntr\/ntab183","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T11:34:02Z","timestamp":1631100842000},"page":"295-305","source":"Crossref","is-referenced-by-count":23,"title":["Human Abuse Liability Assessment of Tobacco and Nicotine Products: Approaches for Meeting Current Regulatory Recommendations"],"prefix":"10.1093","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2654-9627","authenticated-orcid":false,"given":"Andrea","family":"Vansickel","sequence":"first","affiliation":[{"name":"Regulatory Affairs, Altria Client Services LLC, Richmond, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Baxter","sequence":"additional","affiliation":[{"name":"Clinical Studies, RAI Services Company, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Sherwood","sequence":"additional","affiliation":[{"name":"Independent Consultant, Nyon, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kong","sequence":"additional","affiliation":[{"name":"Altasciences Clinical Research, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Campbell","sequence":"additional","affiliation":[{"name":"Clinical Studies, RAI Services Company, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"2022021412050969700_CIT0001","author":"Royal College of Physicians.","year":"2016"},{"key":"2022021412050969700_CIT0002","author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products.","year":"2012"},{"key":"2022021412050969700_CIT0003","author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Tobacco Products.","year":"2019"},{"key":"2022021412050969700_CIT0004","article-title":"21 CFR Parts 1100, 1107, and 1114. [Docket No. FDA\u20132019\u2013N\u20132854] RIN 0910\u2013AH44","volume":"Vol. 84","author":"U.S. Department of Health and Human Services, Food and Drug Administration.","year":"2019","journal-title":"Federal Register"},{"key":"2022021412050969700_CIT0005","author":"World Health Organization.","year":"2003"},{"key":"2022021412050969700_CIT0006","first-page":"945","article-title":"The scientific basis of tobacco product regulation: report of a WHO Study Group.","author":"World Health Organization.","year":"2007","journal-title":"WHO Technical Reports Series"},{"issue":"2","key":"2022021412050969700_CIT0007","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/tc.2003.006890","article-title":"Reducing tobacco addiction through tobacco product regulation","volume":"13","author":"Henningfield","year":"2004","journal-title":"Tob Control."},{"issue":"1","key":"2022021412050969700_CIT0008","first-page":"127","article-title":"Could science-based regulation make tobacco products less addictive?","volume":"3","author":"Henningfield","year":"2002","journal-title":"Yale J Health Policy Law Ethics."},{"key":"2022021412050969700_CIT0009","author":"SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks) of the European Commission.","year":"2010"},{"key":"2022021412050969700_CIT0010","author":"European Union Tobacco Products Directive II.","year":"2014","journal-title":"Officials Journal of the European Union"},{"key":"2022021412050969700_CIT0011","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.yrtph.2019.02.011","article-title":"Assessment of priority tobacco additives per the requirements of the EU Tobacco Products Directive (2014\/40\/EU): Part 1: Background, approach, and summary of findings","volume":"104","author":"Simms","year":"2019","journal-title":"Regul Toxicol Pharmacol."},{"key":"2022021412050969700_CIT0012","author":"SCHEER (Scientific Committee on Health, Environmental and Emerging Risks).","year":"2016"},{"key":"2022021412050969700_CIT0013","author":"World Health Organization Report on the Global Tobacco Epidemic, 2021: Addressing new and emerging products.","year":"2021"},{"key":"2022021412050969700_CIT0014","first-page":"967","author":"World Health Organization.","year":"2012","journal-title":"WHO Technical Reports Series"},{"key":"2022021412050969700_CIT0015","author":"U.S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).","year":"2017"},{"issue":"3 Suppl","key":"2022021412050969700_CIT0016","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0376-8716(03)00098-X","article-title":"Principles of initial experimental drug abuse liability assessment in humans","volume":"70","author":"Griffiths","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"2022021412050969700_CIT0017","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/7854_2016_448","article-title":"The abuse potential of prescription opioids in humans-closing in on the first century of research","volume":"34","author":"Walsh","year":"2017","journal-title":"Curr Top Behav Neurosci."},{"key":"2022021412050969700_CIT0018","author":"U.S. Food and Drug Administration."},{"issue":"12","key":"2022021412050969700_CIT0019","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1158\/1055-9965.EPI-09-0948","article-title":"Abuse liability assessment of tobacco products including potential reduced exposure products","volume":"18","author":"Carter","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"3\u20134","key":"2022021412050969700_CIT0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00213-005-0054-z","article-title":"Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone","volume":"184","author":"DeNoble","year":"2006","journal-title":"Psychopharmacology (Berl)."},{"key":"2022021412050969700_CIT0021","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drugalcdep.2016.08.628","article-title":"Abuse liability assessment of an e-cigarette refill liquid using intracranial self-stimulation and self-administration models in rats","volume":"168","author":"LeSage","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"2022021412050969700_CIT0022","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.drugalcdep.2009.04.003","article-title":"Principles of laboratory assessment of drug abuse liability and implications for clinical development","volume":"105 (Suppl 1)","author":"Carter","year":"2009","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"2022021412050969700_CIT0023","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0091-3057(02)00723-2","article-title":"Flavor improvement does not increase abuse liability of nicotine chewing gum","volume":"72","author":"Houtsmuller","year":"2002","journal-title":"Pharmacol Biochem Behav."},{"issue":"4","key":"2022021412050969700_CIT0024","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s002130050250","article-title":"Nicotine nasal spray and vapor inhaler: abuse liability assessment","volume":"130","author":"Schuh","year":"1997","journal-title":"Psychopharmacology (Berl)."},{"issue":"1","key":"2022021412050969700_CIT0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/pm\/pnw122","article-title":"Abuse potential with oral route of administration of a Hydrocodone extended-release tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users","volume":"18","author":"Darwish","year":"2017","journal-title":"Pain Med."},{"issue":"5","key":"2022021412050969700_CIT0026","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/jcp.0b013e3181515205","article-title":"Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users","volume":"27","author":"Parasrampuria","year":"2007","journal-title":"J Clin Psychopharmacol."},{"issue":"5","key":"2022021412050969700_CIT0027","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/ntr\/ntr257","article-title":"Evaluation of the effect of ammonia on nicotine pharmacokinetics using rapid arterial sampling","volume":"14","author":"McKinney","year":"2012","journal-title":"Nicotine Tob Res."},{"issue":"11","key":"2022021412050969700_CIT0028","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1073\/pnas.0909184107","article-title":"Kinetics of brain nicotine accumulation in dependent and nondependent smokers assessed with PET and cigarettes containing 11C-nicotine","volume":"107","author":"Rose","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"2022021412050969700_CIT0029","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1037\/0022-006X.61.5.743","article-title":"Nicotine delivery kinetics and abuse liability","volume":"61","author":"Henningfield","year":"1993","journal-title":"J Consult Clin Psychol."},{"issue":"1","key":"2022021412050969700_CIT0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/clpt.1988.107","article-title":"Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum","volume":"44","author":"Benowitz","year":"1988","journal-title":"Clin Pharmacol Ther."},{"issue":"5","key":"2022021412050969700_CIT0031","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/tc.2008.028993","article-title":"Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers","volume":"19","author":"Cobb","year":"2010","journal-title":"Tob Control."},{"issue":"2","key":"2022021412050969700_CIT0032","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/tc.2006.018440","article-title":"Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge","volume":"16","author":"Kotlyar","year":"2007","journal-title":"Tob Control."},{"issue":"8","key":"2022021412050969700_CIT0033","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1055-9965.EPI-10-0288","article-title":"A clinical laboratory model for evaluating the acute effects of electronic \u201ccigarettes\u201d: nicotine delivery profile and cardiovascular and subjective effects","volume":"19","author":"Vansickel","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"1","key":"2022021412050969700_CIT0034","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/ntr\/nts123","article-title":"Determination of nicotine absorption from multiple tobacco products and nicotine gum","volume":"15","author":"Digard","year":"2013","journal-title":"Nicotine Tob Res."},{"issue":"7","key":"2022021412050969700_CIT0035","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00213-018-4904-x","article-title":"Assessment of the abuse liability of three menthol Vuse Solo electronic cigarettes relative to combustible cigarettes and nicotine gum","volume":"235","author":"Stiles","year":"2018","journal-title":"Psychopharmacology (Berl)."},{"issue":"4","key":"2022021412050969700_CIT0036","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/ntr\/ntq003","article-title":"Evaluating oral noncombustible potential-reduced exposure products for smokers","volume":"12","author":"Blank","year":"2010","journal-title":"Nicotine Tob Res."},{"issue":"9","key":"2022021412050969700_CIT0037","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/14622200802323258","article-title":"Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology","volume":"10","author":"Gray","year":"2008","journal-title":"Nicotine Tob Res."},{"issue":"5","key":"2022021412050969700_CIT0038","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1037\/pha0000261","article-title":"Abuse liability assessment of an electronic cigarette in combustible cigarette smokers","volume":"27","author":"Maloney","year":"2019","journal-title":"Exp Clin Psychopharmacol."},{"issue":"8","key":"2022021412050969700_CIT0039","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/j.1360-0443.2012.03791.x","article-title":"Clinical laboratory assessment of the abuse liability of an electronic cigarette","volume":"107","author":"Vansickel","year":"2012","journal-title":"Addiction."},{"key":"2022021412050969700_CIT0040","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.yrtph.2015.12.003","article-title":"A randomised, crossover study on an electronic vapour product, a nicotine inhalator and a conventional cigarette. Part A: Pharmacokinetics","volume":"74","author":"Walele","year":"2016","journal-title":"Regul Toxicol Pharmacol."},{"key":"2022021412050969700_CIT0041","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1186\/s12889-015-2349-2","article-title":"Nicotine delivery, tolerability and reduction of smoking urge in smokers following short-term use of one brand of electronic cigarettes","volume":"15","author":"D\u2032Ruiz","year":"2015","journal-title":"BMC Public Health."},{"issue":"e1","key":"2022021412050969700_CIT0042","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1136\/tobaccocontrol-2015-052447","article-title":"Electronic cigarette nicotine delivery can exceed that of combustible cigarettes: a preliminary report","volume":"25","author":"Ram\u00f4a","year":"2016","journal-title":"Tob Control."},{"issue":"3","key":"2022021412050969700_CIT0043","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/add.13183","article-title":"Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes","volume":"111","author":"St Helen","year":"2016","journal-title":"Addiction."},{"issue":"1","key":"2022021412050969700_CIT0044","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ntr\/ntr316","article-title":"Electronic cigarettes: effective nicotine delivery after acute administration","volume":"15","author":"Vansickel","year":"2013","journal-title":"Nicotine Tob Res."},{"issue":"e1","key":"2022021412050969700_CIT0045","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1136\/tobaccocontrol-2016-053041","article-title":"Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second-generation and third-generation electronic cigarette users","volume":"26","author":"Wagener","year":"2017","journal-title":"Tob Control."},{"issue":"4","key":"2022021412050969700_CIT0046","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2174\/1570159X15666171016164430","article-title":"E-cigarettes: impact of E-liquid components and device characteristics on nicotine exposure","volume":"16","author":"DeVito","year":"2018","journal-title":"Curr Neuropharmacol."},{"issue":"2","key":"2022021412050969700_CIT0047","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00213-013-3249-8","article-title":"Acute electronic cigarette use: nicotine delivery and subjective effects in regular users","volume":"231","author":"Dawkins","year":"2014","journal-title":"Psychopharmacology (Berl)."},{"key":"2022021412050969700_CIT0048","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1038\/srep04133","article-title":"Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices","volume":"4","author":"Farsalinos","year":"2014","journal-title":"Sci Rep."},{"issue":"12","key":"2022021412050969700_CIT0049","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1158\/1055-9965.EPI-09-0971","article-title":"Measures for assessing subjective effects of potential reduced-exposure products","volume":"18","author":"Hanson","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"2022021412050969700_CIT0050","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/FBP.0b013e328337be68","article-title":"The effects of nicotine, denicotinized tobacco, and nicotine-containing tobacco on cigarette craving, withdrawal, and self-administration in male and female smokers","volume":"21","author":"Barrett","year":"2010","journal-title":"Behav Pharmacol."},{"issue":"2","key":"2022021412050969700_CIT0051","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14622200110042636","article-title":"Withdrawal-suppressing effects of a novel smoking system: comparison with own brand, not own brand, and de-nicotinized cigarettes","volume":"3","author":"Buchhalter","year":"2001","journal-title":"Nicotine Tob Res."},{"issue":"2\u20133","key":"2022021412050969700_CIT0052","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.drugalcdep.2011.03.026","article-title":"Oral tobacco products: preference and effects among smokers","volume":"118","author":"Hatsukami","year":"2011","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"2022021412050969700_CIT0053","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00213-002-1361-2","article-title":"Subjective effects of the nicotine lozenge: assessment of abuse liability","volume":"167","author":"Houtsmuller","year":"2003","journal-title":"Psychopharmacology (Berl)."},{"key":"2022021412050969700_CIT0054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7517-8-1","article-title":"US smokers\u2019 reactions to a brief trial of oral nicotine products","volume":"8","author":"O\u2032Connor","year":"2011","journal-title":"Harm Reduct J."},{"issue":"4","key":"2022021412050969700_CIT0055","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/BF02247470","article-title":"Nicotine discrimination in male and female smokers","volume":"116","author":"Perkins","year":"1994","journal-title":"Psychopharmacology (Berl)."},{"issue":"1","key":"2022021412050969700_CIT0056","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/14622200020032123","article-title":"Subjective and discriminative stimulus effects of two de-nicotinized cigarettes with different tar yields","volume":"3","author":"Schuh","year":"2001","journal-title":"Nicotine Tob Res."},{"issue":"3","key":"2022021412050969700_CIT0057","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s002130000382","article-title":"A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler","volume":"149","author":"West","year":"2000","journal-title":"Psychopharmacology (Berl)."},{"issue":"5","key":"2022021412050969700_CIT0058","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.addbeh.2006.06.028","article-title":"Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire","volume":"32","author":"Cappelleri","year":"2007","journal-title":"Addict Behav."},{"issue":"1","key":"2022021412050969700_CIT0059","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14622200020032051","article-title":"Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings","volume":"3","author":"Cox","year":"2001","journal-title":"Nicotine Tob Res."},{"key":"2022021412050969700_CIT0060","article-title":"A consortium approach for consumer-reported outcome measures for assessing tobacco and\/or nicotine-containing products","author":"Acquadro"},{"issue":"11","key":"2022021412050969700_CIT0061","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/ntr\/ntx228","article-title":"Consortium on methods evaluating tobacco: research tools to inform US Food and Drug Administration Regulation of Snus","volume":"20","author":"Berman","year":"2018","journal-title":"Nicotine Tob Res."},{"issue":"2","key":"2022021412050969700_CIT0062","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s002130000660","article-title":"Threshold doses for nicotine discrimination in smokers and non-smokers","volume":"155","author":"Perkins","year":"2001","journal-title":"Psychopharmacology (Berl)."},{"issue":"4","key":"2022021412050969700_CIT0063","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s002130050304","article-title":"Nicotine discrimination and self-administration in humans as a function of smoking status","volume":"131","author":"Perkins","year":"1997","journal-title":"Psychopharmacology (Berl)."},{"key":"2022021412050969700_CIT0064","article-title":"Acute nicotine reinforcement requires ability to discriminate the stimulus effects of nicotine","author":"Perkins","journal-title":"Exp Clin Psychopharmacol"},{"issue":"1","key":"2022021412050969700_CIT0065","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1037\/1064-1297.4.1.97","article-title":"Validation of the multiple-choice procedure for investigating drug reinforcement in humans","volume":"4","author":"Griffiths","year":"1996","journal-title":"Exp Clin Psychopharmacol"},{"issue":"2","key":"2022021412050969700_CIT0066","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00213-004-1818-6","article-title":"Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers","volume":"175","author":"Harvey","year":"2004","journal-title":"Psychopharmacology (Berl)."},{"issue":"5","key":"2022021412050969700_CIT0067","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/0091-3057(83)90099-0","article-title":"Cigarette smokers self-administer intravenous nicotine","volume":"19","author":"Henningfield","year":"1983","journal-title":"Pharmacol Biochem Behav."},{"issue":"1","key":"2022021412050969700_CIT0068","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1037\/1064-1297.16.1.57","article-title":"Further validation of a cigarette purchase task for assessing the relative reinforcing efficacy of nicotine in college smokers","volume":"16","author":"MacKillop","year":"2008","journal-title":"Exp Clin Psychopharmacol."},{"issue":"3","key":"2022021412050969700_CIT0069","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14622200410001696547","article-title":"Rate of nicotine onset from nicotine replacement therapy and acute responses in smokers","volume":"6","author":"Perkins","year":"2004","journal-title":"Nicotine Tob Res."},{"issue":"2","key":"2022021412050969700_CIT0070","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s002130051162","article-title":"Comparing the reinforcing efficacy of nicotine containing and de-nicotinized cigarettes: a behavioral economic analysis","volume":"147","author":"Shahan","year":"1999","journal-title":"Psychopharmacology (Berl)."},{"issue":"4","key":"2022021412050969700_CIT0071","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.npp.1301460","article-title":"Self-administration of intravenous nicotine in male and female cigarette smokers","volume":"33","author":"Sofuoglu","year":"2008","journal-title":"Neuropsychopharmacology."},{"issue":"2","key":"2022021412050969700_CIT0072","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-016-4455-y","article-title":"Naturalistic assessment of demand for cigarettes, snus, and nicotine gum","volume":"234","author":"Stein","year":"2017","journal-title":"Psychopharmacology (Berl)."},{"issue":"3","key":"2022021412050969700_CIT0073","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.beproc.2011.05.002","article-title":"Influence of escalating alternative reinforcer values on cigarette choice","volume":"87","author":"Stoops","year":"2011","journal-title":"Behav Processes."},{"key":"2022021412050969700_CIT0074","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.drugalcdep.2017.06.004","article-title":"The experimental tobacco Marketplace II: substitutability and sex effects in dual electronic cigarette and conventional cigarette users","volume":"178","author":"Quisenberry","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"2022021412050969700_CIT0075","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ntr\/ntr137","article-title":"Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette dependence","volume":"14","author":"Fagerstr\u00f6m","year":"2012","journal-title":"Nicotine Tob Res"},{"key":"2022021412050969700_CIT0076","author":"U.S. Food and Drug Administration."}],"container-title":["Nicotine &amp; Tobacco Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ntr\/advance-article-pdf\/doi\/10.1093\/ntr\/ntab183\/40441055\/ntab183.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ntr\/article-pdf\/24\/3\/295\/42514467\/ntab183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ntr\/article-pdf\/24\/3\/295\/42514467\/ntab183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T12:40:26Z","timestamp":1644842426000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ntr\/article\/24\/3\/295\/6367135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,9,9]]},"published-print":{"date-parts":[[2022,2,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ntr\/ntab183","relation":{},"ISSN":["1469-994X"],"issn-type":[{"value":"1469-994X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,9,9]]}}}